<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="B01AC56" />
<ATC code="C10BX01" />
<ATC code="C10BX02" />
<ATC code="C10BX04" />
<ATC code="M01BA03" />
<ATC code="N02BA01" />
<ATC code="N02BA51" />
<ATC code="N02BA71" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>Not recommended with</SEVERITY>
<COMMENT>-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<DRUG name="DEXTRAN 40" rxcui="42635">
<ATC code="B03AC06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
